| REVIEW ARTICLE |
|
| Year : 2022 | Volume
: 5
| Issue : 1 | Page : 35-38 |
|
|
Role of axitinib and other tyrosine kinase inhibitors in the management of metastatic renal cell carcinoma
Sagar Bhagat, Nishtha Khatri, Saiprasad Patil, Hanmant V Barkate
Global Medical Affairs, Glenmark Pharmaceuticals Ltd, Mumbai, Maharashtra, India
Correspondence Address:
Dr. Nishtha Khatri
Global Medical Affairs, Glenmark Pharmaceuticals Ltd, Mumbai, Maharashtra
India
 Source of Support: None, Conflict of Interest: None
DOI: 10.4103/jco.jco_5_22
|
|
|
The selection of chemotherapeutic agents in the management of metastatic renal cell carcinoma is a challenge as it has to strike a delicate balance between adverse effects and patient affordability based on the individual risk stratification. In this narrative review, authors have discussed about the various tyrosine kinase inhibitors available and the preference for axitinib as the first-line drug when used as a single agent or in combination with immunotherapeutic agents. This review article has been written based on a literature search of relevant articles conducted from September 2020 to December 2020 across PubMed and Google Scholar. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
